Literature DB >> 36161509

ZIM3 activation of CCL25 expression in pulmonary metastatic nodules of osteosarcoma recruits M2 macrophages to promote metastatic growth.

Jing Li1, Chenguang Zhao2, Dong Wang1, Shuang Wang3, Hui Dong4, Difan Wang5, Yubing Yang1, Jiaxi Li1, Feng Cui1, Xijing He6, Jie Qin7.   

Abstract

Tumor-associated macrophages (TAMs) play an important role in tumor growth and metastasis. However, the involvement of TAMs infiltration in pulmonary osteosarcoma (OS) metastasis remains poorly understood. Therefore, the effect of OS cells on macrophages migration was investigated by in vivo and in vitro experiments to evaluate the infiltration and mechanism of TAMs in pulmonary OS metastases. The results showed that the zinc finger protein ZIM3 was upregulated in OS cells than in osteoblasts and activated the expression of CCL25, which subsequently promoted the migration of M2 macrophages. CCL25 or ZIM3 silencing in OS cells inhibited the infiltration of M2 macrophages and the formation of pulmonary metastatic nodules in a mouse model of pulmonary OS metastasis and prolonged the survival of the mice. Furthermore, bioinformatics analyses revealed that CCL25 and ZIM3 expressions are negatively correlated with the prognosis of OS patients. In conclusion, this study found that a large number of M2 TAMs were recruited into pulmonary metastatic nodules of OS through the activation of the ZIM3-CCL25 axis in OS cells, thereby facilitating OS metastasis. Therefore, the suppression of ZIM3-CCL25-induced recruitment of M2 TAMs to the metastatic sites might be considered as a therapeutic approach to inhibit the growth of pulmonary OS metastases.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  CCL25; M2 macrophages; Migration; Osteosarcoma; ZIM3

Year:  2022        PMID: 36161509     DOI: 10.1007/s00262-022-03300-7

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.630


  56 in total

1.  Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  P G Casali; S Bielack; N Abecassis; H T Aro; S Bauer; R Biagini; S Bonvalot; I Boukovinas; J V M G Bovee; B Brennan; T Brodowicz; J M Broto; L Brugières; A Buonadonna; E De Álava; A P Dei Tos; X G Del Muro; P Dileo; C Dhooge; M Eriksson; F Fagioli; A Fedenko; V Ferraresi; A Ferrari; S Ferrari; A M Frezza; N Gaspar; S Gasperoni; H Gelderblom; T Gil; G Grignani; A Gronchi; R L Haas; B Hassan; S Hecker-Nolting; P Hohenberger; R Issels; H Joensuu; R L Jones; I Judson; P Jutte; S Kaal; L Kager; B Kasper; K Kopeckova; D A Krákorová; R Ladenstein; A Le Cesne; I Lugowska; O Merimsky; M Montemurro; B Morland; M A Pantaleo; R Piana; P Picci; S Piperno-Neumann; A L Pousa; P Reichardt; M H Robinson; P Rutkowski; A A Safwat; P Schöffski; S Sleijfer; S Stacchiotti; S J Strauss; K Sundby Hall; M Unk; F Van Coevorden; W T A van der Graaf; J Whelan; E Wardelmann; O Zaikova; J Y Blay
Journal:  Ann Oncol       Date:  2018-10-01       Impact factor: 32.976

Review 2.  Current and future therapeutic approaches for osteosarcoma.

Authors:  Douglas J Harrison; David S Geller; Jonathan D Gill; Valerae O Lewis; Richard Gorlick
Journal:  Expert Rev Anticancer Ther       Date:  2017-12-14       Impact factor: 4.512

3.  Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC.

Authors:  Xuanwen Bao; Run Shi; Tianyu Zhao; Yanfang Wang; Natasa Anastasov; Michael Rosemann; Weijia Fang
Journal:  Cancer Immunol Immunother       Date:  2020-07-17       Impact factor: 6.968

Review 4.  Metastatic osteosarcoma: a challenging multidisciplinary treatment.

Authors:  Cristina Meazza; Paolo Scanagatta
Journal:  Expert Rev Anticancer Ther       Date:  2016-04-06       Impact factor: 4.512

Review 5.  A Breakthrough: Macrophage-Directed Cancer Immunotherapy.

Authors:  Charles D Mills; Laurel L Lenz; Robert A Harris
Journal:  Cancer Res       Date:  2016-01-15       Impact factor: 12.701

6.  Lysyl-tRNA synthetase-expressing colon spheroids induce M2 macrophage polarization to promote metastasis.

Authors:  Seo Hee Nam; Doyeun Kim; Doohyung Lee; Hye-Mi Lee; Dae-Geun Song; Jae Woo Jung; Ji Eon Kim; Hye-Jin Kim; Nam Hoon Kwon; Eun-Kyeong Jo; Sunghoon Kim; Jung Weon Lee
Journal:  J Clin Invest       Date:  2018-10-08       Impact factor: 14.808

Review 7.  Harnessing tumor-associated macrophages as aids for cancer immunotherapy.

Authors:  Xiaolei Li; Rui Liu; Xiao Su; Yongsha Pan; Xiaofeng Han; Changshun Shao; Yufang Shi
Journal:  Mol Cancer       Date:  2019-12-05       Impact factor: 27.401

8.  Tumor microenvironment characterization identifies two lung adenocarcinoma subtypes with specific immune and metabolic state.

Authors:  Jianbing Huang; Jiagen Li; Sufei Zheng; Zhiliang Lu; Yun Che; Shuangshuang Mao; Yuanyuan Lei; Ruochuan Zang; Chengming Liu; Xinfeng Wang; Lingling Fang; Nan Sun; Jie He
Journal:  Cancer Sci       Date:  2020-04-17       Impact factor: 6.716

Review 9.  Macrophages, as a Promising Strategy to Targeted Treatment for Colorectal Cancer Metastasis in Tumor Immune Microenvironment.

Authors:  Yingru Zhang; Yiyang Zhao; Qi Li; Yan Wang
Journal:  Front Immunol       Date:  2021-07-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.